Concentrating on what is in front of them instead of what might be in the future , O ’ Neill says involvement with THC might not totally be out of the question . “ I think , at some point in time if we found the right partners already licensed in certain jurisdictions , and we knew there was a clear way forward , we might take a look , but for now we ’ re staying away from that aspect .” Biomedican alludes to the fact the traditional way of producing rare cannabinoids through plants — interrupted production cycles with varying limited yield — is now passé , superceded by the biosynthesis method of manipulating organisms to produce select compounds as pharmaceutical giant Eli Lilly did in managing bacteria and yeast in order to manufacture insulin . So , the concept of biosynthesis isn ’ t new , but the manipulation of the selected host organism , Yarrowia Lypolitica , is . Under proprietary methodology , splicing yeast DNA produces cannabinoids biologically identical to those produced by the plant itself . Yarrowia is part of a fungal family of oleaginous yeasts whose cells are made up of more than 20 percent fat . “ There are competitors in this space , some of them charlatans — and we ’ re not saying we own this space . We just think we have the best technology in the field by creating the highestquality product at the lowest-cost of anyone else . If we ’ re not number one in this biosynthesis space , we ’ re in the top three in a multi-billion market — estimated to be $ 10 billion by 2025 ,” predicts O ’ Neill . As new markets open up , the cannabinoid industry overall is expected to grow exponentially to a licit global market of $ 146 billion over the next five years according to one estimate by Grand View Research .
Currently engaged in raising additional millions of dollars for further research and development and to fund large-scale production and arrange contract manufacturing , “ We want to become a supplier to companies with large-scale distribution systems that work , like those in the health industry who deal with CBD and CBDA . Those with distribution networks are going to find a new way of making money through us by offering new products they couldn ’ t offer before . At a later date , we ’ ll decide if we want to launch our own brand and have our own manufacturing facility to selectively target branding within that space .”
“
Splicing yeast DNA produces cannabinoids biologically identical to those produced by the plant itself .”
One obvious advantage of the chemical production of the materials versus large field operations ( the growharvest-extract method ) is that indoor laboratory production facilities would come at far less cost than what would be needed for thousands of field acres , while managed output would have the potential to exceed conventional growing methods . “ We ’ re hoping to help millions of people with all types of medical conditions access these rare cannabinoids to help them mitigate their conditions and reduce pain and suffering . Our discovery should open a lot of doors , especially in the arenas of anti-inflammatories and neuroprotectives , and we expect to have more in those areas within six months .” The company timeline has pre-orders anticipated in three to six months with large-scale production underway within 12 months . “ We ’ ve delivered more results in a shorter period of time with less money than anybody else in our space . We ’ ve quickly raised $ 3.5 million and we have strategic partnerships with multiple universities around the world .”
Reaction to this new way of doing things is starting to roll in . Biofuels Digest , billed as ‘ The World ’ s Most Widely-Read Biofuels Daily ’, noted : “ The ability to cheaply and rapidly mass-produce highly-desired cannabinoids such as THC and CBD , as well as the more than 200 less-understood cannabinoids without the need for a conventional growing operation , presents a compelling investment opportunity both from the current demand for the well-known cannabinoids as well as the many of the lesser-known which scientists continue to research for novel , medical , therapeutic , and alternative purposes .”
Green Rush Daily , commenting on the advantages of biosynthesizing cannabinoids , reported : “ From an industry perspective , the advantages are numerous starting with simple efficiency . Instead of spending millions on massive cultivation operations , producing and processing hundreds of thousands of plants , companies could bypass the entire grow cycle of the plant and simply produce cannabinoids in isolation — quicker , at a fraction of the cost of traditional farming , and with a smaller environmental footprint .”
Maximum Yield 95